JAK3 and ulcerative colitis: Tofacitinib is an oral JAK-1 and JAK-3 inhibitor that has been approved for the treatment of rheumatoid arthritis and ulcerative colitis, plaque psoriasis, atopic dermatitis, vitiligo, and alopecia areata.